Central Valley Advisors’s DexCom DXCM Stock Holding History

Central Valley Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8,709	Closed	-$1.21M	–	151
2024 Q1	$1.21M	Buy	+8,709	New	+$1.09M	0.62%	47

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Central Valley Advisors's DXCM Position: Q2 2024 in Review

Central Valley Advisors sold out of DexCom (DXCM) in Q2 2024, closing a stake of 8,709 shares — an estimated $1.21M sold.

Central Valley Advisors first reported a position in DXCM in Q1 2024 and held it in 1 quarter. The position peaked at $1.21M in Q1 2024. 1,000 funds tracked by Wall St. Rank hold DXCM as of Q2 2024.

Central Valley Advisors reported no remaining DexCom position as of Q2 2024 after selling out during the quarter.
Central Valley Advisors sold 8,709 DexCom shares in Q2 2024, an estimated $1.21M.
Central Valley Advisors first reported a position in DexCom in Q1 2024 and held it in 1 quarter.
Central Valley Advisors's DexCom position peaked at $1.21M in Q1 2024.
1,000 funds tracked by Wall St. Rank held DexCom as of Q2 2024.

Based on Central Valley Advisors's 13F filing for Q2 2024, filed 12 Jul 2024.